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CannabisSensorimotor gating, measured as themodiﬁcation of eye blink startle reﬂexes to loud acoustic stimuli by quieter
preceding stimuli, is altered in those with psychosis, their relatives and those at high clinical risk for psychosis.
Alterations have also been shown in cannabis users, albeit to a lesser extent, and cannabis is a known risk factor
for the onset of psychosis in clinically and genetically susceptible individuals.
We examined the interaction between clinical risk for psychosis and cannabis use on sensorimotor gating, both
Prepulse Inhibition (PPI) and Prepulse Facilitation (PPF). We tested PPI and PPF in participants with an At Risk
Mental State (ARMS) for psychosis and a matched control group. Both groups included a proportion of subjects
who had recently used cannabis, as conﬁrmed by urinary drug screening (UDS) on the day of testing. We found
that ARMS participants showed reduced PPF and PPI relative to controls, the latter driven by a group by cannabis
use interaction, with recent use reducing PPI in ARMS participants but not in controls. When the analysis was
limited to UDS-negative participants there was signiﬁcantly reduced PPF in ARMS subjects relative to controls,
but no differences in PPI. Within the ARMS group reduced sensorimotor gating, measured by both PPI and PPF,
related to reduced overall level of function.
Cannabis use in clinical high risk individuals may increase the risk of psychosis in part through worsening PPI,
while PPF is altered in ARMS individuals irrespective of cannabis use. This develops our understanding of
cognitive mechanisms leading to the experience of aberrant perceptual phenomena and the subsequent
development of psychotic symptoms.
© 2015 Published by Elsevier B.V.1. Introduction
Sensorimotor gating is thought to play a role in how organisms
allocate limited cognitive resourceswithin a sensorially rich environment.
Measuring the eyeblink startle reﬂex to a strong sensory stimulus, or
‘pulse’, can be used to study aspects of sensorimotor gating by examining
the effect of a relatively weak preceding ‘prepulse’ (PP). This PP modiﬁes
the extent of the startle that follows according to the delay between
stimuli, the inter-stimulus interval (ISI). When the ISI is short, between
30 and 480 ms, the startle reﬂex to the pulse that follows is attenuated,
a phenomenon known as prepulse inhibition (PPI); with a longer ISI,
between 500 and 2000 ms, the startle reﬂex to the following pulse is
augmented, known as prepulse facilitation (PPF). PPI and PPFmay reﬂect
distinct processes: PPI at short ISI is thought to represent primarily an
automatic pre-attentive gating mechanism (Braff et al., 1992), while
attentional modulation of PPI occurs with ISI greater than 100 ms (Braff
et al., 2001). PPF may represent later stages of sensory processingry, De Crespigny Park, London,
ton-Brown).such as generalized alerting, orientation and passive attention
(Graham, 1975).
In patients with psychotic disorders, deﬁcits in sensorimotor gating
may lead to cognitive fragmentation disorganization and psychotic
symptoms, but the stage at which processing is altered is unknown
(Kapur, 2003). Deﬁcits in PPI in subjects with schizophrenia are well
established (reviewed in Braff et al., 2001), and have been related to
cognitive impairments and positive psychotic symptoms (Kumari
et al., 2008c), and have been correlated with reductions in dorsolateral
prefrontal, middle frontal and orbital/medial prefrontal volume (Kumari
et al., 2008b). PPI deﬁcits have also been reported in people with
schizotypal (Cadenhead et al., 2000; Cadenhead, 2011) and psychosis-
prone personality traits (Swerdlow et al., 1995a; Kumari et al., 2008a),
and in the relatives of people with schizophrenia (Cadenhead et al.,
2000; Kumari et al., 2005). These data suggest that PPI deﬁcits may be a
marker of vulnerability for psychosis.
There have been several previous studies of PPI in people at clinical
high risk for psychosis. Quednow et al. (2008) found diminished PPI in
this group, whereas Cadenhead (2011) found no differences between
high risk subjects and controls, but increased PPI in high risk subjects
who later developed psychosis relative to that in subjects who did not.
More recently both Ziermans et al. (2011) and De Koning et al. (2014)
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out drug using participants using urinary testing. Biomarkers of clinical
outcomes in this group are of particular interest, as they may facilitate
the stratiﬁcation of high risk samples according to the likelihood
that an individual will subsequently develop psychosis or recover
(Fusar-poli et al., 2012). Studies of PPI in this group also have the
advantage of being free of the potentially confounding effects of
antipsychotic medication on PPI (Kumari et al., 2007), as clinical
high risk subjects are often medication naive.
Although there have been several studies of PPI in relation to
psychosis, there have been relatively few studies of PPF (reviewed in
Kumari et al., 2004, Schiz Res, Appendix 1/2). Wynn et al. (2004)
found reduced PPF in subjects with schizophrenia and their ﬁrst degree
relatives compared to controls. There have not been any studies of PPF
in subjects at clinical high risk.
A large proportion of patients with psychotic disorders and subjects
at high risk of psychosis use psychoactive substances, particularly
cannabis. Cannabis use can induce acute psychotic symptoms and is
associated with an increased risk of developing a psychotic disorder
(Arseneault et al., 2004;Moore et al., 2007). Little is known of the effects
of substance use on PPI or PPF in either clinical or healthy samples, and
the importance of UDS screening is well known (Swerdlow et al.,
1995b). One study found PPI deﬁcits in cannabis-using healthy controls
only in actively attended to trials (Kedzior and Martin-Iverson,
2006)—in these attentional modulation paradigms participants are
instructed to actively attend to prepulse and pulse sounds, compared
to passive attention designs where no such direction is given. Similar
ﬁndings emerged from a later study that compared cannabis using
and non-using subjects with schizophrenia alongside healthy controls
(Scholes-Balog and Martin-Iverson, 2011). Administering cannabinoids
during adolescence to mice reproduced PPI deﬁcits and several other
markers of schizophrenia, (Gleason et al., 2012) and these were reversed
by antipsychotic treatment (Nagai et al., 2006).
In the present study we set out to examine both PPI and PPF of the
acoustic startle reﬂex inmedication-free subjectswith anAt RiskMental
State for psychosis (Yung et al., 2005). They were compared with
demographically- and geographically-matched healthy controls, and
urinary drug screening was used to test for cannabis and other
psychoactive substances. Our main hypothesis was that ARMS subjects
would show PPI and PPF deﬁcits relative to controls. A secondary
hypothesis was that the ﬁndings would be modulated by cannabis
use.
2. Methods
2.1. Recruitment
27 ARMS participants were recruited from Outreach And Support in
South London (Fusar-Poli et al., 2013), a clinical service for the treatment
of people at high risk of psychosis. At intake they were assessed by a
psychiatrist using the Comprehensive Assessment of At Risk Mental
States (Yung et al., 2005), and ARMS status was conﬁrmed by consensus
at multidisciplinary teammeeting. All patients were antipsychotic naïve.
27 healthy control (HC) participants were recruited from the same
geographical area, from the friends of the ARMS participants and via
local advertisements. Control participants were excluded if they had a
personal or family history of neurological or psychiatric disorder.
Written informed consent was obtained, and the local Research
Ethics Committee approved the study protocol. Participants received
compensation for their time and travel.
Prior to testing, all participants were assessed by a psychiatrist
(TWB) and clinical scales were administered as follows: Hamilton
Anxiety and Depression rating scales (Hamilton, 1960, 1959), Compre-
hensive Assessment of At Risk Mental States (CAARMS (Yung et al.,
2005), and Peters Delusion Inventory (PDI Peters et al., 2004). Predicted
IQ was estimated using the National Adult Reading Test (NART Nelson,1991). Around half of the participants also participated in a separate
session as part of another study where the history of substance use
and their overall level of use for each substance was quantiﬁed on a
scale of 0–4 (0 = never; 1 = experimental use, has tried occasionally,
2 = occasional use, has tried small quantitates from time to time;
3=moderate use, has used small quantities regularly or large quantities
occasionally; 4 = severe use, has frequently used large quantities,
Table 2).2.2. Protocol
A commercially available human startle responsemonitoring system
(Mark II, SR-Lab, SanDiego, California)was used to generate and deliver
the acoustic stimuli, and to record and score the electromyographic
(EMG) activity for 250ms starting from the onset of the acoustic startle
stimulus. Acoustic stimuli were presented to participants binaurally
through well-sealed headphones (Telephonics TDH-39P). The pulse-
alone stimulus was a 40-ms presentation of 114-dB (A) white noise
and the prepulse stimulus a 20-ms presentation of 85-dB (A) white
noise, both over 70-dB (A) continuous back-ground noise. The noise
levels were calibrated using the continuous noise, and checked and re-
calibrated on a monthly basis.
The session began with a 5 min acclimatization period consisting of
70 dB(A) continuous white noise. During the experiment, participants
received four blocks of 21 trials each, after an initial pulse-alone trial;
each block consisted of 3 pulse alone (PA) trials, 3 prepulse alone
(PP) trials, 3 prepulse trials with a 30-ms prepulse-to-pulse (onset-to-
onset) interval (PPI30), 3 prepulse trials with a 60-ms prepulse-to-pulse
interval (PPI60), 3 prepulse trials with a 120-ms prepulse-to-pulse inter-
val (PPI120), 3 prepulse trials with a 1000 ms prepulse-to-pulse interval
(1000) and 3 prepulse trials with a 2000 ms prepulse-to-pulse interval
(PPF2000). Trials were presented to participants in a pseudorandom
order with a mean inter-trial interval of 15 s (range 9–23 s). The
experiment lasted for 25 min, including the acclimation period.
The experimental procedures for recording and scoring the startle
reﬂexes have been described in detail previously (e.g. Kumari et al.,
2012). The eye blink component of the startle was indexed by recording
EMG activity of the orbicularis oculi muscle directly beneath the right
eye, using two miniature silver/silver chloride electrodes. Recorded
EMG activity was band-pass ﬁltered at 50-Hz, as recommended by the
SR-Lab. The EMGdatawereﬁrst inspected on a trial-to-trial basis ofﬂine,
then scored using the analytic program of this system for response
amplitude (in arbitrary analogue-to-digital units; one unit = 2.62 μV)
and latencies to response onset and peak. Responses were rejected if
the onset and peak latencies differed by more than 95 ms, or when
the baseline values shifted by more than 50 units (6.59% of trials).
Noisy recordings, indicated by a high number of rejected trials (N30%),
were rejected outright; this led to 3 ARMS subjects and 4 HC subjects
being excluded from analysis, leaving 23HC and 24HC subjects included
in the ﬁnal analysis.
PPI and PPF were computed for each participant separately for each
trial type and block. PPI was calculated as (a− b / a) × 100, where “a”=
pulse-alone amplitude and “b” = amplitude over prepulse trials. PPF
was the inverse calculation: (b− a / a) × 100. Percent of PPI/PPF, rather
than absolute amount (i.e. arithmetic difference between pulse-alone
and prepulse trials), was used since this procedure reduces the inﬂuence
of individual differences in startle responsiveness (Csomor et al., 2008).
Psychophysiological data were scored blind to diagnosis and group
membership.
Participants were told that the purpose of the experiment was to
measure their reaction to a number of noise-bursts; no instruction
was given on whether to attend or ignore them. They were asked to
keep their eyes open during the experiment. Participants who smoked
tobacco were not excluded, but they were not admitted to the testing
suite until at least 30 minutes after their last cigarette, to minimize the
Table 2
Self reported substance use history.
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PPF (Postma et al., 2001; Swerdlow et al., 1996).ARMS HC Statistic
(t / x2) / p
Any illicit drugs—ever used? (y/n) 10/4 8/6 0.62/0.430
Cannabis—ever used? (y/n) 10/4 10/4 0.27/0.605
Cannabis—frequency of use (0–4)—mean (SD) 1.9 (1.6) 1.1 (1.2) 1.57/0.131
Amphetamine—ever used? (y/n) 5/9 2/12 1.71/0.190
Amphetamine—frequency (0–4)—mean (SD) 0.9 (1.3) 0.2 (0.4) 1.70/0.101
Cocaine—ever used? (y/n) 4/10 2/12 0.85/0.357
Cocaine—frequency (0–4)—mean (SD) 0.8 (1.5) 0.1 (0.4) 1.58/0.126
Ecstasy—ever used? (y/n) 4/10 3/11 0.19/0.663
Ecstasy—frequency (0–4)—mean (SD) 0.7 (1.2) 0.2 (0.4) 1.47/0.1552.3. Analysis
Group differences in demographic and clinical measures were
compared using chi-squared or paired t-tests.
Habituation over four blocks of pulse-alone trials was tested by
entering the response amplitude of these trials into a repeatedmeasures
analysis of variance (ANOVA) with block as a within subject variable
and group (HC, ARMS) as a between subject variable. Subsequent
analyses used the mean measure across all blocks but also examined
effects within the ﬁrst block alone.
Separate analyses were undertaken for PPI and PPF. To examine
group differences, PPI/PPF (%) scores were subjected to a 2 (Group:
HC, ARMS) × 3/2 (Trial type: 30-ms, 60-ms and 120-ms prepulse trials
for PPI, 1000-ms and 2000-ms for PPF) ANOVA, with group as a
between-subjects and trial-type as a within-subject factor. This was
followed by an ANCOVA to rule out confounding effects of gender
(Aasen et al., 2005; e.g. Swerdlow et al., 1996) and smoking status.
To examine the effects of illicit substances, the analyseswere repeated
adding current cannabis use (UDS positive) as an additional between-
subject factor. ANCOVAs were then conducted to rule out confounding
effects of smoking and gender. Signiﬁcant main effects were explored
with planned post hoc pairwise comparisons using Tukey's Least
Signiﬁcant Difference measure. If the UDS was positive for substances
in addition to cannabis (cocaine and amphetamine), these analyses
were then repeated excluding these subjects.
In order to test relationships with clinical parameters, mean PPI at
60 ms and PPF at 1000 ms were testing using Spearman's correlations
with total CAARMS positive score, Hamilton-A, Hamilton-D and Global
Assessment of Functioning (GAF) score.3. Results
Therewere no differences between groups on demographicmeasures
(Table 1) or on self-reported substance use history (Table 2). As expected,
all clinical measures were signiﬁcantly greater in the ARMS group
(Table 1). There were 6 ARMS and 5 HC subjects who tested positive for
cannabis on the UDS. One of these ARMS subjects also tested positive
for cocaine, and another also tested positive for cocaine and
amphetamine. There were no differences on demographic or clinical
measures between UDS positive and negative subjects within either
group.Table 1
Demographics and clinical measures of subjects included in ﬁnal analysis.
ARMS HC Statistic (t / x2) / p
n 24 23 -
Age—mean (SD) 22.0 (3.5) 23.5 (4.0) 1.39/ 0.172
Gender (F/M) 13/11 8/15 0.621/ 0.73
Smoker 13 8 0.181
UDS positive 6 5 0.792
Predicted IQ (NART)—mean (SD) 110 (9.5) 114 (11.4) 1.241/0.22
CAARMS—pos mean (SD) 7.62 (3.1) 0.8 (1.2) 9.5/ b0.0001
Ham-A—mean (SD) 15.0 (6.9) 2.0 (3.2) 8.0/ b0.0001
Ham-D—mean (SD) 14.5 (8.2) 1.6 (2.3) 7.1/ b0.0001
SPQ-B—mean (SD) 13.3 (3.8) 4.6 (4.5) 7.43/ b0.0001
PDI—mean (SD) 66.1 (39.5) 22.7 (23.5) 4.22/ b0.0001
GAF—mean (SD) 54.9 (6.6) 81.9 (10.7) 7.76/ b0.0001
UDS Urinary Drug Screen; NART National Adult Reading Test; CAARMS Comprehensive
Assessment of At Risk Mental States; Ham-A Hamilton Anxiety Rating Scale; Ham-D
Hamilton Depression Rating Scale; SPQ-B Schizotypy Personality Questionnaire Brief;
PDI Peters Delusional Index; GAF Global Assessment of Functioning.4. Habituation
There was a signiﬁcant effect of block on startle amplitude to pulse
alone trials, which decreased over subsequent blocks (Fig. 1, F = 12.9
df= 3, p b 0.0001), with no effect of group (F= 0.32, df= 1, p= 0.57)
or group × block interaction (F = 0.027, df = 1, p = 0.871). To allow
for this habituation in subsequent analyses we re-examined effects
found across all blocks in the ﬁrst block alone.
5. Startle reactivity
Startle reactivity was calculated by measuring the mean amplitude
of the response to the pulse alone trials in the 4 blocks. An initial
ANOVA was performed with block as within subject factor and group
as a between subject factor. There was a signiﬁcant effect of block
(F= 12.882 df= 3 p b 0.001) but no group × block interaction. When
substance use was added as an additional between subject factor this
was not altered and there was no main effect of substance use or
group × substance use interaction.
We then re-examined startle reactivity to the pulse alone trials from
the ﬁrst block by performing a univariate ANOVA with group and
substance use as between subject variables. There was no effect of
substance use or group, and no group × substance use interaction.
Finally we re-examined startle reactivity to the ﬁrst pulse alone trial
only. There was a trend to an effect of substance use (F= 3.468 df= 1
p = 0.07): those positive on UDS had reduced amplitude of startle
reactivity to the ﬁrst pulse alone trial in both groups but there was no
main effect of group or group by drug interaction (Fig. 2, Supplementary
Table 2). To account for thiswe added startle amplitude to theﬁrst pulse
alone trial as an additional covariate in the PPI and PPF analyses where
drug use was included as a between subject factor.
6. PPI
The ANOVA of mean PPI with trial-type as a within subject factor,
and group as a between subject factor revealed no main effect ofFig. 1. Signiﬁcant habituation across blocks, error bars represent +/−1 SEM.
Fig. 2. Amplitude of reaction to the ﬁrst pulse by group and drug.
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covariates did not alter this result. However, when current substance
use (UDS positive) was added as an additional between-subject
variable, there was a signiﬁcant group × substance use interaction
(F = 4.478, df= 1 error df= 43 p = 0.04). This interaction remained
signiﬁcantwhen the substance effectswere restricted to those of cannabis
alone (by excluding the 2 subjects who were also positive for cocaine,
F = 5.01 df = 1 error df = 41 p = 0.031), and when smoking
(group × substance use interaction: F = 4.361 df = 1 error df = 42
p = 0.043, effect of smoking: F = 0.107 df = 1 error df = 42 p =
0.745) and gender (group × substance use interaction: F = 4.521 df=
1 error df = 42 p = 0.039, effect of gender: F = 7.97 df = 1 error
df=42 p=0.007) were added as covariates. Adding overall mean star-
tle response amplitude reduced the signiﬁcance of the interaction
(group × substance use interaction: F = 3.274 df = 1 error df = 42
p = 0.018, effect of startle response F = 0.511 df = 1 error df = 37
p= 0.497).
When these analyses were repeated using PPI from the ﬁrst block
alone, the ANOVA of 1st block PPI with trial type as a within-subject
factor, and group and drug as between-subject factors revealed a signiﬁ-
cant main effect of group (F= 5.84 df= 1 error df= 43 p= 0.02), and
a signiﬁcant group × drug interaction (F = 8.37 df = 1 error df = 43
p=0.006): ARMS subjects had reduced PPI overall compared to controls,
and in controls cannabis use was associated with increased PPI, whereas
the opposite applied in ARMS subjects. Both these ﬁndings were stronger
when the substance use effects were restricted to cannabis alone (group
effect F= 8.994 df= 1 error df= 41 p= 0.005, Fig. 3A, Supplementary
Table 3A, group × substance use interaction: F = 11.88 df = 1 error
df=41 p=0.001, Fig. 3B, Supplementary Table 3B). They also remained
signiﬁcant when gender (group effect F = 4.805 df= 1 error df= 42
p = 0.034, group × substance use interaction F = 8.149 df = 1 p =
0.007, effect of gender F = 2.595 df = 1 error df = 42 p = 0.115)
smoking (group effect F = 4.636 df = 1 error df = 42 p = 0.037,
group × substance use interaction F= 8.389 df= 1 df= 42 p= 0.006,
effect of smoking F= 1.812 df= 1 error df= 42 p= 0.185) and mean
1st block startle response amplitude were added as covariates to
these analyses (group effect F = 5.832 df = 1 df = 42 p = 0.02,Fig. 3. A) Mean 1st block PPI type by group, and 3B) by grogroup × substance use interaction F = 4.774 df = 1 error df = 42
p = 0.035, effect of startle response F = 11.176 df = 1 error df =
42 p = 0.002).
7. PPF
Identical analyses were conducted for PPF. The ANOVA of mean PPF
with trial-type as awithin subject factor and group as a between subject
factor revealed a trend towards amain effect of group (F=3.317 df=1
error df=40 p=0.076), with a reduction in PPF in ARMS subjects. This
was not altered by addingmean startle amplitude as a covariate (group
effect F=2.896 df=1error df=39 p=0.097, effect of startle response
F = 1.429 df = 1 error df = 39 p = 0.239) and was strengthened by
adding gender as a covariate (group effect F = 5.104 df = 1 error
df = 39 p = 0.03, effect of gender F = 4.353 df = 1 error df = 39
p = 0.044) and by adding smoking additionally (group effect F =
4.539 df = 1 error df = 39 p = 0.04, effect of smoking F = 0.287
df=1 error df=38 p=0.595). Adding current substance use as an ad-
ditional between subject-factor did not reveal a signiﬁcant
group × substance use interaction.
We repeated the above analyses using PPF from the ﬁrst block alone.
Again there was a trend towards an effect of group (F = 3.65 df = 1
error df= 40 p= 0.063), PPF was reduced in ARMS relative to control
participants. This effectwas not altered by addingmean startle amplitude
from the ﬁrst block (group effect F = 3.079 df = 1 error df = 39 p =
0.087, effect of startle response F = 0.524, df = 1 error df = 39 p =
0.524) but was strengthened by adding gender as a covariate (group
effect F = 4.454 df = 1 error df = 39 p = 0.041, effect of gender F =
1.391 df= 1 error df=39 p= 0.245) and by adding smoking addition-
ally (group effect F = 4.507 df = 1 error df = 38 p = 0.04, effect of
smoking F= 0.155 df=1 error df= 38 p= 0.696, Fig. 4A, Supplemen-
tary Table 4A). Adding current substance use as an additional between
subject-factor did not reveal a signiﬁcant group × substance use interac-
tion (Fig. 4B, Supplementary Table 4B).
8. PPI and PPF in UDS negative participants
We repeated the main analyses after excluding all subjects with a
positive urinary drug screen. In UDS negative subjects there was no
main effect of group for mean or 1st block PPI, but there was a trend
for an effect of group for mean PPF (F = 3.023 df = 1 error df = 30
p= 0.092) which was stronger in the 1st block (F= 3.94 df= 1 error
df=30 p=0.056), and signiﬁcantwhen sex and smokingwere included
as covariates (group effect F = 5.360 df = 1 error df = 30 p = 0.028,
effect of gender F = 1.323 df = 1 error df = 28 p = 0.260, effect of
smoking F= 0.772 df= 1 error = 28 p= 0.387).
9. Relationship of PPF and PPI to clinical measures
Within the ARMS, there were no signiﬁcant correlations between
mean PPI at 60 ms and mean PPF at 1000 ms and CAARMS positive,
PDI, SPQ-B, Ham-A or Ham-D scores. Signiﬁcant correlations wereup and cannabis use. Error bars represent +/−1 SEM.
Fig. 4. A) Mean 1st block PPF type by group, and 4B) by group and cannabis use. Error bars represent +/− 1 SEM.
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(ρ=−0.502, p= 0.021 (and PPF at 1000 ms (ρ= 0.529, p= 0.024).
10. Relationship of PPF and PPI to cannabis use
Within those who tested positive for cannabis use, there was no
correlation between the between mean PPI at 60 ms and mean PPF at
1000 ms self reported frequency of cannabis use.
11. Discussion
We tested PPI andPPF of the eyeblink startle reﬂex to acoustic stimuli
in participants at high clinical risk for psychosis and a matched control
group. Both groups included a proportion of subjects who had recently
used psychoactive substances, primarily cannabis, as conﬁrmed by
urinary drug screening on the day of testing. Because there was
signiﬁcant habituation across blocks we tested 1st block trials
alone as well as all trials together. In the 1st block ARMS participants
showed reduced PPI relative to controls, and this appeared to be
driven by a group by cannabis use interaction, with recent use reducing
PPI in ARMS participants but not in controls. When the analysis was
limited to UDS-negative participants there was signiﬁcantly reduced
PPF in ARMS subjects relative to controls, but no differences in PPI. PPI
and PPF both related to overall function in the ARMS as measured by
the GAF.
A reduction in PPI in ARMS participants is consistentwith the type of
deﬁcit evident in participants with psychotic disorders (Parwani et al.,
2000; Wynn et al., 2004), their relatives (Kumari et al., 2005), and in
people with psychosis-prone personalities (Kumari et al., 2008a). This
suggests that PPI may represent a biomarker for vulnerability to
psychosis, and adds weight to evidence of the validity of the Attenuated
Psychosis Syndrome that has been much debated in DSM-V (Ruhrmann
et al., 2010). However, our ﬁndings also suggest that cannabis use has
differential effects on PPI in ARMS and controls; when cannabis users
were excluded from the analyses PPI in the ARMS group was normal. In
previous studies of PPI where urine testing for recent substance use was
not conducted, including in samples of psychotic subjects (Parwani
et al., 2000) and in clinical (Quednow et al., 2008), and genetic (Wynn
et al., 2004) high risk samples, this raises the possibility that these
ﬁndings may have been confounded by the effects of cannabis use. A
further possibility is that thosewhowere positive for cannabis on urinary
testing are ‘true’ at risk for psychosis participantswhose altered PPI is part
of the prodrome of later psychosis. The present cross sectional data are
unable to answer this interesting possibility.
A differential effect of cannabis on PPI in high risk subjects is in line
with evidence of the symptomatic effects of cannabis in this group
(Henquet et al., 2005; van Os et al., 2010). It is also consistent with
evidence that effects of cannabis use on psychotic symptoms and onthe risk of developing a psychotic disorder are moderated by genetic
risk for psychosis and speciﬁc polymorphisms (Caspi et al., 2005;
Henquet et al., 2008).
A differential effect of cannabis attenuating PPI in high risk subjects
is also consistent with evidence that chronic cannabis users have
reduced PPI, although only in attended-to trials (Kedzior and Martin-
Iverson, 2006), and that drug free chronic cannabis users have PPI
comparable to controls (Quednow et al., 2004). The ﬁnding of increased
PPI in cannabis positive controls meanwhile is similar to another recent
study (Preller et al., 2013) and consistentwith evidence that CB1 agonists
similarly induced PPI increases in rodents (Long et al., 2010; Stanley-Cary
and Harris, 2002).
It is plausible that some of the psychoactive effects of cannabis in
susceptible individuals are via effects on sensorimotor gating, both at
early and later stages: in rats, agonists to the CB1 receptor, the principal
target of THC in the brain, reduce prepulse inhibition, reversed by
haloperidol (Schneider and Koch, 2002), and modulate emotional
associative learning and memory formation (Laviolette and Grace,
2006). In humans Delta-9-tetrahydrocannabinol (THC), the key
psychoactive constituent of cannabis, alters neural responses during
basic sensory processing (Winton-Brown et al., 2011) and attentional
oddball processing (Bhattacharyya et al., 2012), the latter particularly in
the striatum and prefrontal cortex (Bhattacharyya et al., 2012). Alter-
ations in so called ‘salience processing’ which may incorporate both
early and late sensorimotor gating (Winton-Brown et al., 2014), induced
by cannabis in susceptible individuals, may lead to the detection and
prominence of stimuli that should have been ﬁltered out, and induction
of psychotic symptoms (Bhattacharyya et al., 2012; Kapur, 2003).
Cannabis did not appear to differentially alter sensorimotor gating at
a later stage, as indexed by PPF. PPF was however signiﬁcantly reduced
in ARMS participants who were UDS-negative, suggesting that there
may be later stage gating abnormalities in people at high risk of psychosis.
These are similar to the ﬁndings from a study that found that PPI in the
siblings of patients with schizophrenia was not different from controls,
but that PPF was signiﬁcantly reduced (Wynn et al., 2004).
We did not ﬁnd relationships between either PPI or PPF and positive
psychotic symptoms, consistentwithprevious literature suggesting that
gating deﬁcits relate more to cognitive deﬁcits and disorganization
(Braff et al., 1999; Karper et al., 1996). We did however ﬁnd relation-
ships of PPI and PPF sensorimotor gating with overall function, similar
to Swerdlow et al. (2006) in participants with schizophrenia.
Our study had a number of important limitations, including a modest
sample size; the subsample of UDS positive participants was particularly
small with 5 and 6 in control and UHR groups respectively. The ﬁndings
should be thus regarded as preliminary and require replication in larger
samples. A limited sample size may also have limited the study's power
to detect PPI deﬁcits in the ARMS group regardless of cannabis use.
However given the marked effects of cannabis use on PPI, in this sample
26 T. Winton-Brown et al. / Schizophrenia Research 164 (2015) 21–27future studies should include urinary drug itmay be useful to collectmore
detailed information on the pattern and experience of substance use.
12. Conclusions
In this sample of subjects at high clinical risk for psychosis, we found
deﬁcits in both early and late stage sensorimotor gating,with the former
moderated by cannabis use. Further work is needed to uncover the
neural basis of sensory gating deﬁcits and how these relate to aberrant
salience and the development of psychotic symptoms.
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